SCHEMBL4334597

SCHEMBL4334597

O=C(Nc1ccc2ncccc2c1)c1nc(Cc2cccnc2)n2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PABPC1 P11940 1/20 0.48
NAMPT P43490 2/20 0.46
NPC1 O15118 10/20 0.45
RAB9A P51151 9/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
POLB P06746 2/20 0.45
MAPT P10636 2/20 0.45
SMN1; SMN2 Q16637 4/20 0.44
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
ALDH1A1 P00352 3/20 0.42
HTT P42858 1/20 0.42
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4335813 0.85 PDE4A (0.52) NAMPTNPC1RAB9APOLBSMN1; SMN2
SCHEMBL4320261 0.85 ATR (0.51) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL4329117 0.85 ROCK2 (0.44) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL4326402 0.83 NPC1 (0.51) NPC1MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL4332695 0.83 RAB9A (0.46) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL4332310 0.83 ATR (0.47) NPC1RAB9ASMN1; SMN2ALDH1A1HTT
SCHEMBL4323530 0.82 NPC1 (0.55) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL4324559 0.81 HTT (0.52) RAB9AMEN1KMT2APOLBMAPT
SCHEMBL4322895 0.81 KDM4E (0.47) NAMPTKMT2APOLBALDH1A1HTT
SCHEMBL4322905 0.79 ATR (0.47) NAMPTALDH1A1HTTPDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325936-A1 IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES MERCK & CO., INC. 2009-12-31 US disclosed
US-20090325936-A1 IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES MERCK & CO., INC. 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325936-A1 IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES CNR2, CNR1, TRPV1 PABPC1 4483/4885NAMPT 1659/4885NPC1 1236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.